Author/Authors :
Chinh Chung، Doan نويسنده Faculty of Biology, University of Science, Vietnam National University, Ho Chi Minh City, Vietnam , , Thanh Long، Le نويسنده Department of Animal Biotechnology, Institute of Tropical Biology, Vietnam Academy of Science and Technology, Ho Chi Minh City, Vietnam , , Nghia Son، Hoang نويسنده Department of Animal Biotechnology, Institute of Tropical Biology, Vietnam Academy of Science and Technology, Ho Chi Minh City, Vietnam , , Tri Bao، Le نويسنده School of Biotechnology, International University, Vietnam National University, Ho Chi Minh City, Vietnam , , Minh Si، Do نويسنده Faculty of Biology, University of Science, Vietnam National University, Ho Chi Minh City, Vietnam , , Van Dong، Le نويسنده Department of Immunology, Vietnam Military Medical University, Ha Noi City, Vietnam ,
Abstract :
Objective: Hepatocellular carcinoma (HCC), one of the most common cancers worldwide,
is resistant to anticancer drugs. Angiogenesis is a major cause of tumor resistance to
chemotherapy, and vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis.
The purpose of this study is to investigate the impact of small-interfering RNA
targeting VEGF gene (VEGF-siRNA) on chemosensitivity of HCC cells in vitro.
Materials and Methods: In this experimental study, transfection was performed on Hep3B
cells. After transfection with siRNAs, VEGF mRNA and protein levels were examined. Cell
proliferation, apoptosis and anti-apoptotic gene expression were also analyzed after treatment
with VEGF-siRNA in combination with doxorubicin in Hep3B cells.
Results: Transfection of VEGF-siRNA into Hep3B cells significantly reduced the expression
of VEGF at both mRNA and protein levels. Combination therapy with VEGF-siRNA
and doxorubicin more effectively suppressed cell proliferation and induced apoptosis than
the respective monotherapies. This could be explained by the significant downregulation
of B-cell lymphoma 2 (BCL-2) and SURVIVIN.
Conclusion: VEGF-siRNA enhanced the chemosensitivity of doxorubicin in Hep3B
cells at least in part by suppressing the expression of anti-apoptotic genes. Therefore,
the downregulation of VEGF by siRNA combined with doxorubicin treatment has
been shown to yield promising results for eradicating HCC cells.